Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 + Tislelizumab for Refractory Malignant Ascites
NCT05303844Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Apr 2022
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oncorine in malignant ascites, sponsored by Fudan University. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Status: unknown.
02
Drugs
Oncorine
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT05303844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303844.